Status and phase
Conditions
Treatments
About
An exploratory open label study to improve the function and welfare of late-stage solid cancer subjects (with or without lung involvement) who failed or refused anti-cancer treatment by ACC treatment, administered orally and concomitantly by inhalation.
The following measures will be evaluated: improvement of pain, performance status, dyspnea measurement (Modified Borg Scale)/ oxygen saturation (if applicable) and overall survival.
The subjects' medical charts will be reviewed for their eligibility including the following: medical history, prior cancer treatments, pathologic diagnosis of cancer, and CT/Chest X-ray results. Assessment of prior and concurrent medication use, physician evaluation of patient status, and measurement of Albumin Corrected Serum Calcium level (to be done at baseline and prior to dose escalation, so that results are available prior to the visit) will be performed prior to each dose escalation; in addition, vital signs, ECOG/Karnofsky performance status and VAS pain assessments will be recorded at each visit as well. CT test will be executed during the study period: at baseline, week 12 and week 24 visits in order to assess progression free survival by CT.
The tests during the visits will be performed by a physician/nurse. Each subject will receive individual doses of AMOR-powder by escalating doses up to 1,800 mg of ACC powder per day (Amor powder administration will be continuous along the day - each eppendorf every two hours). Patients who will not be able to swallow the powder, will receive similar doses of ACC in tablets.
In addition, subject will inhale 1% ACC in 8 ml suspension, for inhalation three times a day.
Subject's functionality will be assessed by serially determining ECOG/Karnofsky performance status. Subject's progression free survival will be assessed by CT to evaluate tumor response to treatment.
Full description
Subjects diagnosed with late stage solid cancer (with or without lung involvement) who failed or refused anti-cancer treatment will be enrolled and administered with both: AMOR powder up to 1800 mg daily and AMOR Inhaled Double Pack 1% ACC in 8 ml suspension - three times a day.
Starting Doses:
1200 mg of AMOR powder (will be administered continuously along the day, each Eppendorf every two hours) scaled up by 200 mg every week until maximum dose of 1,800 mg. Patients who will not be able to swallow the powder, will receive similar doses of ACC tablets.
ACC Amor Inhaled Double Pack; 1% ACC in 8 ml suspension - for inhalation three times a day.
Screening hospital visit:
Baseline (Week 0) hospital visit:
First ACC Dose:
Week 1 (+/- 2 days range) hospital visit:
Week 2 (+/- 2 days range) hospital visit:
Week 3 (+/- 2 days range) hospital visit/ home visit:
Treatment Maintenance:
Week 6 (+/- 2 days range) hospital visit:
Week 12 (+/- 2 days range) hospital visit:
Week 18 (+/- 2 days range) hospital visit:
Week 24 Termination visit (+/- 2 days range) hospital visit:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Males and females, age 18 years +
Signed the informed consent
Late Stage Histologically proven advanced solid tumours for which no standard of care therapy exist or failed or refused anti-cancer treatment
Subject should not have any illness or condition deemed by the physician to contra-indicate treatment with ACC or may interfere with the assessment of the therapy
Performance Status: ECOG 0-3/ Karnofsky performance status >50
Life Expectancy : at least 2 months
Hormonal therapy is allowed if needed
Patient is on conservative treatment for relieving his symptoms
Subjects within normal range of serum-corrected albumin calcium (between 7.0-10.5 mg/dl)
Acceptable haematology and biochemistry variables:
WBC ≥3000/mm3 Absolute Neutrophil count ≥ 1500 /mm3 Platelet Count ≥ 100,000/mm3 Hemoglobin ≥ 9 g/dL Bilirubin ≤ 1.5 x ULN ALT and AST ≤ 2.5 x ULN; for patients with hepatic metastases, ALT and AST ≤ 5 x ULN PT/PTT ≤ 1.5 ULN
Subjects should have sufficient Vitamin D levels upon study entry, which is defined as 25(OH)D serum level >20 ng/mL (50 nmol/L) according to a document composed by the Food and Nutrition Board of the Institute of Medicine, USA. If the subject is Vitamin D insufficient or deficient, then a loading dose of Vitamin D3 will be administered during subject's enrollment or during the study as follows:
Subjects receiving Denosumab or bisphosphonates are eligible. Denosumab or bisphosphonates can be administered during the study to alleviate bone metastasis pain.
Negative Pregnancy Test.
Exclusion criteria
Concurrent treatment with acute anti-cancer therapy
Hypercalcemia or previous consistent reporting of hypercalcemia (serum calcium concentration > 12.0 mg/dL)
Clinical Significant Cardiovascular Disease
Known alcohol or drug abuse
Any psychiatric condition that would prohibit understanding or rendering of Informed Consent
Active Participation in Clinical Trial in the last 2 weeks prior to inclusion
Brain metastases or spinal cord compression unless asymptomatic or treated and stable off steroids and anti-convulsants for at least 1 month prior to study treatment.
Nephrolithiasis
Pregnancy
Primary purpose
Allocation
Interventional model
Masking
11 participants in 1 patient group
Loading...
Central trial contact
Julia Rothman, Dr.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal